NetworkNewsWire Editorial Coverage: More than 700 million people worldwide are affected with some form of mental illness, addiction or eating disorder, representing about 13% of total disease burden. In reality, the worldwide picture is a bit murky, considering the high frequency of nondiagnosis as well as lack of treatment, even in the most developed countries. Advances in medicine to treat these conditions of the brain have been elusive, as conventional drugs that treat symptoms and not underlying causes remain the most popular. There are reasons to be optimistic about the future, though, underscored by increased research activity surrounding psychedelics. This is the area of focus for Cybin Inc. (NEO: CYBN) (Profile), which this week acquired Adelia Therapeutics, a transformational move that broadened addressable indications in its pipeline and strengthened its scientific team. Cybin has a three-pillar approach, its initial sights set on treating major depression disorder (“MDD”) now expanded to address additional indication as well through innovative psychedelic therapeutics development and unique delivery technologies. Cybin stands shoulder-to-shoulder with peers striving for a world of better mental well-being such as COMPASS Pathways Plc (NASDAQ: CMPS), Mind Medicine Inc (OTC: MMEDF) (NEO: MMED), Numinus Wellness Inc. (OTC: LKYSF) (NEO: NUMI) (TSX.V: NUMI) and HAVN Life Sciences (OTC: HAVLF), all of which are developing innovative approaches to bring new psychedelic-based therapies to patients in need.
- Mental health disorders forecast to cost $16 trillion by 2030.
- Cybin’s acquisition of Adelia Therapeutics accelerates growth strategy, bolsters world-class scientific team, increases IP portfolio to seven patent filings.
- The company executes on three-pillar growth plan focused on developing psychedelic-based drug discovery platform, efficient drug-delivery methods, novel treatment regimens.
Time for Effective Options to Alleviate Pain, Financial Strain
More than 700 million people dealing with illnesses takes a toll on health-care systems. By 2030, it is estimated that the aggregate cost of mental health maladies to the global economy could reach a stunning $16 trillion. The problem is not that there aren’t options to treat a disease such as depression; there are many, including selective serotonin reuptake inhibitors (“SSRI”) such as Prozac (fluoxetine), and serotonin and norepinephrine reuptake inhibitors (“SNRI”) such as Effexor XR (venlafaxine).
In fact, more than 40 million Americans take antidepressants or some other type of psychiatric drug. No, the problem is not availability. The problem lies more in conventional drugs often being accompanied by negative side effects and doing more to mask the disease rather than get to the root of the condition.
Meeting Promises
Toronto-based Cybin Inc. (NEO: CYBN) is developing technologies and delivery systems, aiming to improve bioavailability to potentially achieve the desired medicinal effects of psychedelics at low-dosage levels. In its latest move, the company acquired Adelia Therapeutics. The acquisition combines two talented management and scientific teams while also bringing an attractive intellectual property portfolio of seven patent filings with further IP development and expanding Cybin’s focus beyond treatment of MDD to include multiple indications.
“We are thrilled to join forces with Adelia, as we see this transaction as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” said Cybin CEO Doug Drysdale. “Adelia’s focus on creating novel therapeutics, including novel delivery methods and innovative therapeutic regimens can support our goal of creating therapies that result in faster onset of action, smoother pharmacokinetic profiles, shorter treatment durations, and reduced side effects. Leveraging Adelia’s expertise across multiple molecules and multiple indications could potentially allow Cybin to extend its reach and capability to address gaps across a larger domain.”
“Cybin is committed to expansion through strategic M&A opportunities,” he continued. “Today we deliver on that commitment and we will continue to pursue such opportunities to drive growth in the future.”
The acquisition dovetails perfectly with Cybin’s already stated drug-delivery goals, bringing onboard a proprietary drug-delivery platform developed by Adelia for the controlled administration of psychedelic therapies that bypass the problems with conventional administration and liver metabolism.
This move reinforces Cybin’s focus on R&D of next-generation medications based on psilocybin, a nonhabit forming, naturally occurring psychedelic compound found in certain species of so-called “magic” mushrooms, for the treatment of MDD. Clinical studies at Johns Hopkins revealed that psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants actually achieving remission through a four-week follow-up.
Impressive Team Additions
Cybin intends to be a leader in this exciting breakthrough for mental health. In its efforts, the company has assembled an experienced team with a combined 80-plus years in the pharmaceutical industry that recently raised C$45 million in the largest go-public capital raise in the Canadian psychedelic sector and total of C$55 million raised across Seed, Series-A and Series-B financing rounds. Part of that capital is now being deployed in a powerful move to acquire Adelia Therapeutics Inc., further bolstering the fundamental strengths of Cybin.
While raising capital, Cybin shared it three-pillar plan of building a novel drug-discovery platform, developing optimal technology and novel treatment regimens. The IP model is multipronged, covering chemically synthesized molecules, delivery mechanisms, screeners, protocols and new drug formulations alongside a merger and acquisition strategy to acquire proprietary technologies and novel compounds and molecules. Cybin also holds worldwide exclusive rights to sublingual film delivery technology from Intelgenx for the delivery of psilocybin and other psychedelic molecules.
The leadership team joining Cybin is impressive, including co-founder and CEO Alex Nivorozhkin, PhD and co-founder, and president and chief strategy officer Brett J. Greene, both of whom bring decades of experience in psychedelics and drug development and are affiliated with Northeastern University’s world-renowned Center for Drug Discovery in Boston. COO Michael Palfreyman, PhD, DSc., is an accomplished pharmaceutical industry veteran responsible for more than 30 successful clinical programs.
Members of the Adelia team have CV’s steeped in success, such as 35 successful exits, work developing proprietary ketamine analogs, experience with major pharmas (e.g., Johnson&Johnson, Pfizer, Roche), a wealth of highly cited peer-reviewed publications, and oversight in the R&D and commercialization of drugs such as Allegra (fexofenadine), Sabril (vigabatrin), Anzemet (dolasetron), and Vaniqa (eflornithine). The team further brings a Rolodex of major network affiliations, including the likes of Massachusetts Institute of Technology, Harvard, Stanford, Yale and Northeastern University.
An Operating Facility Too
With the acquisition, Cybin is significantly broadening its footprint in the United States. In addition to the reach and esteemed networks of Adelia’s leadership team, the company is also gaining an operating development facility in the epicenter of Boston biotech, a heartbeat of innovation in the country.
“Cybin brings complementary resources to the table, and together we can advance our shared goal of bringing psychedelic therapies across a broad spectrum of indications,” commented Nivorozhkin, who will assume the role of Cybin chief scientific officer upon completion of the acquisition. “[We] look forward to the opportunity to transform the psychedelic therapeutics industry together,” he said.
A Movement Underway
The world is seeing a resurgence in interest in psychedelics after a relative standstill that lasted several decades. Only older generations recall a growing body of evidence supporting the therapeutic advantages of psychedelics before 1970. To the demise of the emerging health-care segment, President Richard Nixon signed the Controlled Substances Act into law that year, outlawing psychedelics as Schedule I drugs with no medicinal benefits.
Small amounts of research in specific academic pockets have been completed over the years, but the acceleration in lab and clinical work has been tied to the legalization of cannabis amid public outcries for new medical options in recent years. Finally, the negative stigma is abating and lawmakers at state and local levels are taking the initiative to open the door to developing new therapies. Following the pioneering lead of Denver, Colorado, three other major U.S. cities have legalized psychedelics in the last year, along with the state of Oregon.
COMPASS Pathways Plc (NASDAQ: CMPS) has effectively served as a tide that has elevated the entire psychedelics space, earning attention from institutions and retail traders alike with a high-profile initial public offering in September and spectacular ascension in value since. From its headquarters in the United Kingdom, COMPASS is regarded by most as the gold standard in psychedelics because it is in mid-stage clinical trials evaluating its synthetic version of psilocybin for use in treatment-resistant depression. The company is developing its psilocybin program for the indication under a Breakthrough Therapy designation from the FDA.
Much like COMPASS, Mind Medicine Inc (OTC: MMEDF) (NEO: MMED) embodies the attention psychedelics are getting, enabling the raising of capital to support large leadership and advisory teams, which includes Bruce Linton, a co-founder and former CEO of Canopy Growth Corp., the largest cannabis company in the world. MindMed is developing several experimental therapies in its pipeline derived from psychedelics without the hallucination effect. The flagship product in 18-MC, which the company is developing to treat the cause of the brain disease that is addiction rather than merely substituting one addictive substance for another less harmful one.
Numinus Wellness Inc. (OTC: LKYSF) (NEO: NUMI) (TSX.V: NUMI) is bringing a diversified approach to the industry to create a mental health company with a complete ecosystem for making psychedelic-assisted psychotherapy available to people in need. Numinus is integrated, with a Health Canada-licensed laboratory for research and analytics services (Numinus Bioscience), a unit (Numinus R&D) for developing new psychedelic-assisted therapeutic protocols and a third division (Numiness Health) that provides treatments to patients through clinical and virtual services. The company can trumpet many first-mover advantages, including being the first company in Canada to receive a license to grow and extract psilocybin from mushrooms, for which the first harvest was recently completed.
HAVN Life Sciences (OTC: HAVLF) is an active part of the Canadian biotech community, researching the benefits of microdosing a variety of psychedelics for hard-to-treat conditions while pursuing standardized extraction of psychoactive compounds under a research license from Health Canada. There is a feel-good component to the HAVN mission in that it works with veterans and military thought leaders in its quest to initiate clinical trials addressing post-traumatic stress disorder (“PTSD”) and other trauma related ailments. A Memorandum of Understanding was inked this month for the purpose of HAVN supplying the international veterans organization Heroic Hearts Project for collaboration on future clinical studies planned to evaluate low doses of ayahuasca, psilocybin and ketamine in mental trauma patients.
The world is witnessing a genuine progression into the opportunity psychedelics present to make a meaningful impact on an area of health care that is ripe for innovation. This movement is quietly being spearheaded by seasoned and successful drug-development veterans and supported by the investment community, providing some real reason for optimism about potential breakthroughs to bridge some large unattended gaps in mental health.
For more information about Cybin Inc., please visit Cybin Inc. (NEO: CYBN)
About NetworkNewsWire
NetworkNewsWire (“NNW”) and PsychedelicNewsWire (“PNW”) are financial news and content distribution companies, two of 50+ brands within the InvestorBrandNetwork (“IBN”), that provide: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
No comments:
Post a Comment